BioTuesdays

Venaxis to merge with Strand Life Sciences

Venaxis (NASDAQ:APPY) has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited and its shareholders. Strand is a privately-held, global genomics and bioinformatics company...

EyeGate starts confirmatory Phase 3 trial in AU

EyeGate Pharmaceuticals (NASDAQ:EYEG) has enrolled the first patient in a confirmatory Phase 3 clinical trial of its EGP-437 combination lead product in patients with non-infectious anterior uveitis, an inflammation of...

Novadaq Q4 revenue to jump about 54%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth...

Can-Fite unveils clinical milestones for 2016

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016.“We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their...

Avivagen issues letter to shareholders

In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans.Mr. Groome said Avivagen continues the process of commercializing its non-antibiotic...

Subscribe

Sign up to our weekly BioTuesdays newsletter.